IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial
This study is ongoing, but not recruiting participants.
Sponsor:
U.S. Army Medical Research and Materiel Command
Collaborators:
Walter Reed Army Institute of Research (WRAIR)
Royal Thai Ministry of Public Health
Mahidol University
Armed Forces Research Institute of Medical Sciences, Thailand
Sanofi Pasteur, a Sanofi Company
Global Solutions for Infectious Diseases
Information provided by (Responsible Party):
U.S. Army Medical Research and Materiel Command
ClinicalTrials.gov Identifier:
NCT00337181
First received: June 14, 2006
Last updated: May 2, 2017
Last verified: May 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This protocol will study the clinical course of HIV-infection among volunteers who have received either a placebo injection or the experimental vaccine combination of ALVAC-HIV and AIDSVAX B/E prior to HIV-1 infection. The study will assess whether those who received the experimental vaccine combination have a slower progression of HIV disease compared to those who received the placebo injection.
| Condition |
|---|
| HIV-1 |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Become HIV-1 Infected During Participation in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX® B/E. |
Resource links provided by NLM:
Further study details as provided by U.S. Army Medical Research and Materiel Command:
| Estimated Enrollment: | 130 |
| Study Start Date: | May 2006 |
| Estimated Study Completion Date: | June 2017 |
| Primary Completion Date: | December 2006 (Final data collection date for primary outcome measure) |
Prospective cohort study of the clinical course of HIV-1 infection occurring after candidate HIV-1 vaccination (breakthrough infection) with ALVAC-HIV (vcP1521) and AIDSVAX B/E. This study will enroll volunteers who become HIV-infected during the course of follow up in a phase III preventive HIV vaccine trial conducted in Rayong and Chon Buri, Thailand. Volunteers will be enrolled in this protocol to provide additional long-term follow up to establish whether differences in viral load after infection (comparing vaccine to placebo) are associated with altered disease outcomes, as well as provide more detailed immunologic and virologic assessment of these volunteers.
Eligibility| Ages Eligible for Study: | 18 Years to 31 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- All individuals who become HIV-infected after receiving experimental vaccine or placebo in the RV144 clinical tria if they received at least injection.
- The volunteer must give written, informed consent.
Exclusion Criteria:
- Persons who have a medical or psychiatric disorder, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.
- Persons who become HIV-infected after the completion of the RV144 protocol.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00337181
Please refer to this study by its ClinicalTrials.gov identifier: NCT00337181
Locations
| Thailand | |
| Chon Buri Regional Hospital | |
| Muang District, Chon Buri Province, Thailand, 20000 | |
Sponsors and Collaborators
U.S. Army Medical Research and Materiel Command
Walter Reed Army Institute of Research (WRAIR)
Royal Thai Ministry of Public Health
Mahidol University
Armed Forces Research Institute of Medical Sciences, Thailand
Sanofi Pasteur, a Sanofi Company
Global Solutions for Infectious Diseases
Investigators
| Principal Investigator: | Supachai Rerks-Ngarm, MD | Ministry of Health, Thailand |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | U.S. Army Medical Research and Materiel Command |
| ClinicalTrials.gov Identifier: | NCT00337181 History of Changes |
| Other Study ID Numbers: |
A-11048 RV152 CBER BB IND-8795 |
| Study First Received: | June 14, 2006 |
| Last Updated: | May 2, 2017 |
| Individual Participant Data | |
| Plan to Share IPD: | No |
Keywords provided by U.S. Army Medical Research and Materiel Command:
|
HIV-1 Natural History HIV vaccine Thailand |
Additional relevant MeSH terms:
|
Vaccines Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 28, 2017